Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yingyi Liu

Showing results (81-90 of 97) with videos related to

Pageof 10
Sort By:
Tropical Animal Health and Production|March 21, 2018
Investigation on pseudorabies prevalence in Chinese swine breeding farms in 2013-2016Yingyi Liu, Shuo Zhang, Qi Xu, et al.
Oncogenesis|June 2, 2022
USP53 plays an antitumor role in hepatocellular carcinoma through deubiquitination of cytochrome cYe Yao, Weijie Ma, Yonghua Guo, et al.
Cephalalgia : an International Journal of Headache|December 9, 2024
Weight loss with atogepant during the preventive treatment of migraine: A pooled analysisB Lee Peterlin, Dale S Bond, Jessica Ailani, et al.
Neurology|June 26, 2024
Efficacy of Atogepant in Chronic Migraine With and Without Acute Medication Overuse in the Randomized, Double-Blind, Phase 3 PROGRESS TrialPeter J Goadsby, Deborah I Friedman, Dagny Holle-Lee, et al.
Molecular Metabolism|July 7, 2022
A novel lncRNA RP11-386G11.10 reprograms lipid metabolism to promote hepatocellular carcinoma progressionKequan Xu, Peng Xia, Xiangdong Gongye, et al.
Cell Death & Disease|May 1, 2021
Serum deprivation-response protein induces apoptosis in hepatocellular carcinoma through ASK1-JNK/p38 MAPK pathwaysXi Chen, Weijie Ma, Ye Yao, et al.
The Journal of Dermatological Treatment|May 2, 2024
Rapid and sustained improvements in itch and quality of life with upadacitinib plus topical corticosteroids in adults and adolescents with atopic dermatitis: 52-week outcomes from the phase 3 AD Up studyNina Magnolo, Michael C Cameron, Mona Shahriari, et al.
Journal of the American Academy of Dermatology|May 25, 2023
Efficacy and safety of switching from dupilumab to upadacitinib versus continuous upadacitinib in moderate-to-severe atopic dermatitis: Results from an open-label extension of the phase 3, randomized, controlled trial (Heads Up)Andrew Blauvelt, Barry Ladizinski, Vimal H Prajapati, et al.
Neurology|December 23, 2024
Early Improvements With Atogepant for the Preventive Treatment of Migraine: Results From 3 Randomized Phase 3 TrialsRichard B Lipton, Pranav Gandhi, Cristina Tassorelli, et al.
Hepatology (Baltimore, Md.)|September 7, 2023
LIM domain only 7 negatively controls nonalcoholic steatohepatitis in the setting of hyperlipidemiaTiangen Wu, Xi Chen, Kequan Xu, et al.
Pageof 10

Showing results (81-90 of 97) with videos related to

Sort By:
Pageof 10
Tropical Animal Health and Production|March 21, 2018
Investigation on pseudorabies prevalence in Chinese swine breeding farms in 2013-2016Yingyi Liu, Shuo Zhang, Qi Xu, et al.
Oncogenesis|June 2, 2022
USP53 plays an antitumor role in hepatocellular carcinoma through deubiquitination of cytochrome cYe Yao, Weijie Ma, Yonghua Guo, et al.
Cephalalgia : an International Journal of Headache|December 9, 2024
Weight loss with atogepant during the preventive treatment of migraine: A pooled analysisB Lee Peterlin, Dale S Bond, Jessica Ailani, et al.
Neurology|June 26, 2024
Efficacy of Atogepant in Chronic Migraine With and Without Acute Medication Overuse in the Randomized, Double-Blind, Phase 3 PROGRESS TrialPeter J Goadsby, Deborah I Friedman, Dagny Holle-Lee, et al.
Molecular Metabolism|July 7, 2022
A novel lncRNA RP11-386G11.10 reprograms lipid metabolism to promote hepatocellular carcinoma progressionKequan Xu, Peng Xia, Xiangdong Gongye, et al.
Cell Death & Disease|May 1, 2021
Serum deprivation-response protein induces apoptosis in hepatocellular carcinoma through ASK1-JNK/p38 MAPK pathwaysXi Chen, Weijie Ma, Ye Yao, et al.
The Journal of Dermatological Treatment|May 2, 2024
Rapid and sustained improvements in itch and quality of life with upadacitinib plus topical corticosteroids in adults and adolescents with atopic dermatitis: 52-week outcomes from the phase 3 AD Up studyNina Magnolo, Michael C Cameron, Mona Shahriari, et al.
Journal of the American Academy of Dermatology|May 25, 2023
Efficacy and safety of switching from dupilumab to upadacitinib versus continuous upadacitinib in moderate-to-severe atopic dermatitis: Results from an open-label extension of the phase 3, randomized, controlled trial (Heads Up)Andrew Blauvelt, Barry Ladizinski, Vimal H Prajapati, et al.
Neurology|December 23, 2024
Early Improvements With Atogepant for the Preventive Treatment of Migraine: Results From 3 Randomized Phase 3 TrialsRichard B Lipton, Pranav Gandhi, Cristina Tassorelli, et al.
Hepatology (Baltimore, Md.)|September 7, 2023
LIM domain only 7 negatively controls nonalcoholic steatohepatitis in the setting of hyperlipidemiaTiangen Wu, Xi Chen, Kequan Xu, et al.
Pageof 10